FRIDAY, March 9 (HealthDay News) -- A new silicone-gel breast
implant received conditional approval Friday from the U.S. Food and
Drug Administration. The implant can be used for breast
augmentation in women 22 and older and for breast tissue
reconstruction at any age.
The newest implant, manufactured by Sientra of Santa Barbara,
Calif., becomes the third approved for use in the United States,
joining devices made by Allergan and Mentor. As a condition for
approval, Sientra will continue studies on the implant's long-term
safety, effectiveness and risks of rare diseases, the FDA
"Data on these and other approved silicone-gel filled breast implants continue to demonstrate a reasonable assurance of safety and effectiveness," Dr. William Maisel, deputy director for science in the FDA's Center for Devices and Radiological Health, said in an agency news release.
Silicone breast implants have been controversial for years, with
critics contending that the devices can rupture and leak silicone,
potentially causing a variety of health problems, including cancer
Classified as medical devices, silicone implants are surgically
placed under breast tissue or chest muscle to reconstruct or
augment the breast.
In reconstruction, the implant usually replaces breast tissue
removed because of cancer or trauma or breast tissue affected by a
severe breast abnormality. Another reason is to revise or improve
results from a previous reconstruction surgery, according to the
Similarly, breast augmentation is used to increase breast size
or to improve on previous augmentation surgery.
The FDA approval of Sientra's implant is based on three years of
data from clinical studies on nearly 1,800 patients. Complications
included tightening of the area around the implant, re-operation,
implant removal, uneven appearance and infection, according to the
The company's additional long-term studies will include a
seven-year follow-up of the current participants; a 10-year study
of nearly 5,000 women to monitor long-term complications, including
rheumatoid arthritis, breast and lung cancer; and five studies
focusing on possible links between the new implant and connective
tissue and neurological diseases, brain cancer, cervical/valvular
cancer and lymphoma, the FDA said.
Reaction to the latest approval came swiftly.
Dr. John Oeltjen, an assistant professor of plastic surgery at
the University of Miami School of Medicine, thinks the FDA decision
is a good one.
"The implant from Sientra is like the implants from other companies already marketing implants," he said. "So that's not out of line."
"In general, there are no problems with silicon gel implants," he said. The advantage of silicon gel over saline implants is that the silicon has a more natural look and feel, he added, while saline implants can wrinkle, which can show through the skin.
However, Oeltjen said he would like to see the FDA also allow
marketing of contoured implants, which are not round, but shaped
more like a natural breast.
Dr. Jeffrey C. Salomon, a clinical professor of plastic surgery
at Yale University School of Medicine, noted, "Sientra is a brand
that has been used in Brazil for an extended length of time, and I
doubt that there were concerns about cancer, otherwise the FDA
would have not approved them."
He added, "While the next generation of breast implants is the
so-called form stable variety, those implants have not been
released in the U.S. despite being used throughout the world for a
"The form stable implant does not develop capsular contracture, which is a response by the body to a foreign object and can result in pain and discomfort as the implant is squeezed by fibers created by the immune system," he added. "And that is really the category of breast implant surgeons are anticipating the release of."
Dr. Alan Matarasso, a plastic surgeon at Lenox Hill Hospital and
Manhattan Eye, Ear and Throat Institute in New York City, said:
"This [the FDA decision] is exciting information for patients
because it offers another choice for women undergoing breast cancer
reconstruction or cosmetic breast augmentation."
Silicone gel implants had been banned in the United States for
14 years, until 2006 when the FDA approved the ones made by
Allergan and Mentor for breast reconstructive surgery and for
breast enlargement in women 22 and older.
But, when the ban was lifted, the FDA noted that there wasn't a
lot of data on adverse effects, including what the agency called
"rare events" and "long-term performance." In light of this, the
agency required the manufacturers to do studies on the implants'
safety and performance after their approval.
Then last September, after a contentious two-day hearing, the
FDA ruled that silicone implants were safe and could remain on the
market. However, the agency said at the time that it would work
with manufacturers of the devices approved for use in the United
States to improve studies gauging the health of women who received
The FDA emphasized last year that silicone implants don't last
forever, with as many as half of women with such implants requiring
removal within 10 years of the initial surgery. According to the
agency, one in five women who receives silicone implants to
increase the size of her breasts will need to have the devices
removed within 10 years due to complications. And as many as half
of women who receive implants for reconstruction after breast
surgery will need them removed within the same time frame.
Common complications include: hardening of the area around the
implant; the need for additional surgeries; and implant removal.
Other frequent problems include implant rupture, wrinkling, breast
asymmetry, scarring, pain and infection, the FDA said.
The FDA recommends that women who get silicone implants:
follow-up regularly with their doctor, which includes occasional
MRIs to detect potential ruptures; pay attention to any changes and
notify their health-care provider if they notice any unusual
symptoms such as pain, asymmetry or swelling; and educate
themselves on the signs and symptoms of complications.
"It's important to remember that breast implants are not lifetime devices," Maisel said. "Women should fully understand risks associated with breast implants before considering augmentation or reconstruction surgery, and recognize that long-term monitoring is essential."
According to FDA estimates, 5 million to 10 million women
worldwide have breast implants.
The U.S. Food and Drug Administration has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.